Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty
This study is currently recruiting participants.
Verified December 2010 by The Baruch Padeh Medical Center, Poriya
Sponsor:
The Baruch Padeh Medical Center, Poriya
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
NCT00262574
First received: December 6, 2005
Last updated: August 8, 2011
Last verified: December 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients receiving BNP or nitroglycerin (IV) during the angioplasty procedure. 24 h after the procedure, vascular reactivity will be re-examined using the brachial artery flow-mediated dilatation study. Blood assays for ET-1, pro-BNP, and various inflammatory markers will be checked before and 24 h after the procedure. It is our hypothesis that endothelial function will be better in the BNP treated patients compared to the NTG treated patients
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Artery Disease |
Drug: Nesiritide, |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Supportive Care |
| Official Title: | Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 |
Resource links provided by NLM:
Further study details as provided by The Baruch Padeh Medical Center, Poriya:
Primary Outcome Measures:
- FMD [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 500 |
| Study Start Date: | July 2005 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Nesiritide,
PCI
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:coronary artery disease -
Exclusion Criteria:CHF and/or reduced LV function, or renal failure with Creatinine >2mg%
-
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00262574
Contacts
| Contact: Yonathan Hasin, prof. | 97246652649 | yhasin@poria.health.gov.il |
| Contact: Diab gahnim, Dr |
Locations
| Israel | |
| The Baruch Pade medical center, Poriya | Recruiting |
| Tiberias, Israel, 15208 | |
| Principal Investigator: Yonathan Hasin, Profesor | |
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Investigators
| Principal Investigator: | Mina Arinos | Ministry of Health, Israel |
More Information
No publications provided
| Responsible Party: | prof yonathan hasin, Israell health ministry |
| ClinicalTrials.gov Identifier: | NCT00262574 History of Changes |
| Other Study ID Numbers: | 20020474-Hasin-BNP.CTIL |
| Study First Received: | December 6, 2005 |
| Last Updated: | August 8, 2011 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by The Baruch Padeh Medical Center, Poriya:
|
endothelial disfunction BNP PCI coronary artery disease |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases |
Vascular Diseases Natriuretic Peptide, Brain Natriuretic Agents Physiological Effects of Drugs Pharmacologic Actions Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013